Nifty Pharma jumps 14% YTD, outshines Nifty 50; is there more upside ahead?
Awaiting price reaction for this filing.
The Nifty Pharma index has gained 14.53% year-to-date, significantly outperforming the Nifty 50 which has declined 7.87%, driven by improving earnings visibility, resilient domestic formulations growth, and a rotation into defensive sectors amid market volatility. Brokerages expect healthy year-on-year revenue growth for pharma companies in Q1FY27, led by sustained strength in domestic formulations, though the US business is likely to remain mixed due to pricing erosion and lower generic Revlimid sales. SBI Securities highlighted Sun Pharma, Ajanta Pharma, Alkem Laboratories, Divi's Laboratories and Zydus Lifesciences as preferred long-term picks, with technical indicators showing sustained bullish momentum.